NASDAQ:EDIT Editas Medicine (EDIT) Stock Price, News & Analysis $2.76 +0.09 (+3.37%) Closing price 04:00 PM EasternExtended Trading$2.76 0.00 (0.00%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Editas Medicine Stock (NASDAQ:EDIT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Editas Medicine alerts:Sign Up Key Stats Today's Range$2.67▼$2.8350-Day Range$2.23▼$3.5752-Week Range$1.51▼$4.54Volume1.02 million shsAverage Volume1.62 million shsMarket Capitalization$270.23 millionP/E RatioN/ADividend YieldN/APrice Target$5.40Consensus RatingModerate Buy Company Overview Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology. The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach. In oncology, Editas is advancing programs that modify immune cells to enhance anti-tumor activity. Strategic collaborations with pharmaceutical partners, including a 2015 agreement with Allergan (now part of AbbVie) for ocular disease programs and a partnership with Bristol Myers Squibb’s Juno Therapeutics for engineered cell therapy, have supported the expansion of its research footprint. Editas Medicine operates primarily in North America, conducting clinical studies in the United States and collaborating with academic and clinical research centers globally. The company was co-founded by leading genome scientists, including Feng Zhang of the Broad Institute, and is led by President and CEO James Mullen Jr., whose experience spans leadership roles at several biotechnology and pharmaceutical firms. With a mission to develop precise, durable treatments for patients with severe genetic diseases, Editas continues to advance its proprietary gene-editing platforms through clinical development and strategic partnerships. The company remains committed to rigorous scientific validation and regulatory engagement as it seeks to bring first-in-class genomic medicines to the clinic.AI Generated. May Contain Errors. Read More Editas Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreEDIT MarketRank™: Editas Medicine scored higher than 57% of companies evaluated by MarketBeat, and ranked 229th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingEditas Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEditas Medicine has a consensus price target of $5.40, representing about 95.7% upside from its current price of $2.76.Amount of Analyst CoverageEditas Medicine has only been the subject of 4 research reports in the past 90 days.Read more about Editas Medicine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Editas Medicine are expected to grow in the coming year, from ($1.07) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 55.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.55% of the float of Editas Medicine has been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 7.07.Change versus previous monthShort interest in Editas Medicine has recently decreased by 8.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Editas Medicine this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows9 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,366.00 in company stock.Percentage Held by Insiders3.10% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Editas Medicine's insider trading history. Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDIT Stock News HeadlinesJonesTrading Keeps Their Buy Rating on Editas Medicine (EDIT)May 16, 2026 | theglobeandmail.comEditas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 ...May 14, 2026 | markets.businessinsider.comI wouldn't assume your portfolio is safeJC Parets, CMT and Founder of TrendLabs, warns that a 'Chaos Cycle' is forming in the market - one where damage builds quietly before most investors realize anything is wrong. The pattern: a split forms, money exits one side of the market, and late movers absorb the losses. Parets believes being on the wrong side of this shift could be costly over the next 12 months.May 22 at 1:00 AM | Trend Labs (Ad)Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual MeetingMay 14, 2026 | finance.yahoo.comEditas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual MeetingMay 14, 2026 | globenewswire.comSome Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) EstimatesMay 11, 2026 | finance.yahoo.comEDIT's Q1 Loss Narrower Than Expected, Pipeline in FocusMay 6, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Vertex Pharmaceuticals (VRTX) and Sotera Health (SHC)May 6, 2026 | theglobeandmail.comSee More Headlines EDIT Stock Analysis - Frequently Asked Questions How have EDIT shares performed this year? Editas Medicine's stock was trading at $2.05 at the start of the year. Since then, EDIT shares have increased by 34.6% and is now trading at $2.76. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) released its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $6.37 million. Editas Medicine had a negative net margin of 281.59% and a negative trailing twelve-month return on equity of 677.39%. When did Editas Medicine IPO? Editas Medicine (EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Top institutional shareholders of Editas Medicine include Renaissance Technologies LLC (4.06%), Bank of New York Mellon Corp (0.28%), Bank of America Corp DE (0.14%) and Sei Investments Co. (0.09%). Insiders that own company stock include Gilmore Neil O'neill, Baisong Mei, Bruce Eaton, Linda Burkly, Jessica Hopfield and Amy Parison. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Editas Medicine investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Tesla (TSLA), Enovix (ENVX) and Luminar Technologies (LAZR). Company Calendar Last Earnings5/05/2026Today5/22/2026Jefferies Global Healthcare Conference 20266/04/2026AGM 20266/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 2 days ago, EDIT's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EDIT CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees230Year Founded2013Price Target and Rating Average Price Target for Editas Medicine$5.40 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+95.7%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$160.06 million Net Margins-281.59% Pretax Margin-281.59% Return on Equity-677.39% Return on Assets-58.25% Debt Debt-to-Equity RatioN/A Current Ratio3.22 Quick Ratio3.22 Sales & Book Value Annual Sales$40.52 million Price / Sales6.67 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book55.20Miscellaneous Outstanding Shares97,910,000Free Float94,871,000Market Cap$270.23 million OptionableOptionable Beta2.14 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:EDIT) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
